Literature DB >> 11127722

Screening for prolonged fatigue syndromes: validation of the SOFA scale.

D Hadzi-Pavlovic1, I B Hickie, A J Wilson, T A Davenport, A R Lloyd, D Wakefield.   

Abstract

BACKGROUND: The identification of syndromes characterised by persistent and disabling mental and/or physical fatigue is of renewed interest in psychiatric epidemiology. This report details the development of two specific instruments: the SOFA/CFS for identification of patients with chronic fatigue syndrome (CFS) in specialist clinics and the SOFA/GP for identification of prolonged fatigue syndromes (PFS) in community and primary care settings.
METHODS: Patients with clinical diagnoses of CFS (n = 770) and consecutive attenders at primary care (n = 1593) completed various self-report questionnaires to assess severity of current fatigue-related symptoms and other common somatic and psychological symptoms. Quality receiver operating characteristic curves were used to derive appropriate cut-off scores for each of the instruments. Comparisons with other self-report measures of anxiety, depression and somatic distress are noted. Various multivariate statistical modelling techniques [latent class analysis (LCA), longitudinal LCA] were utilised to define the key features of PFS and describe its longitudinal characteristics.
RESULTS: The SOFA/CFS instrument performs well in specialist samples likely to contain a high proportion of patients with CFS disorders. Cut-off scores of either 1/2 or 2/3 can be used, depending on whether the investigators wish to preferentially emphasise false-negatives or false-positives. Patients from these settings can be thought of as consisting not only of those with a large number of unexplained medical symptoms, but also those with rather specific musculoskeletal and pain syndromes. The SOFA/GP instrument has potential cut-off scores of 1/2 or 2/3, with the latter preferred as it actively excludes all non-PFS cases (sensitivity = 81%, specificity = 100%). Patients with these syndromes in the community represent broader sets of underlying classes, with the emergence of not only musculoskeletal and multisymptomatic disorders, but also persons characterised by significant cognitive subjective impairment. Twelve-month longitudinal analyses of the primary care sample indicated that the underlying class structure was preserved over time. Comparisons with other measures of psychopathology indicated the relative independence of these constructs from conventional notions of anxiety and depression.
CONCLUSIONS: The SOFA/GP instrument (which is considerably modified from the SOFA/CFS in terms of anchor points for severity and chronicity) is preferred for screening in primary care and community settings. Patients with PFS and CFS present a range of psychopathology that differs in its underlying structure, cross-sectionally and longitudinally, from coventional notions of anxiety and depression.

Entities:  

Mesh:

Year:  2000        PMID: 11127722     DOI: 10.1007/s001270050266

Source DB:  PubMed          Journal:  Soc Psychiatry Psychiatr Epidemiol        ISSN: 0933-7954            Impact factor:   4.328


  17 in total

1.  If I am in the mood, I enjoy it: an exploration of cancer-related fatigue and sexual functioning in women with breast cancer.

Authors:  Kate Webber; Kelly Mok; Barbara Bennett; Andrew R Lloyd; Michael Friedlander; Ilona Juraskova; David Goldstein
Journal:  Oncologist       Date:  2011-08-11

Review 2.  Chronic fatigue syndrome: the need for subtypes.

Authors:  Leonard A Jason; Karina Corradi; Susan Torres-Harding; Renee R Taylor; Caroline King
Journal:  Neuropsychol Rev       Date:  2005-03       Impact factor: 7.444

3.  Identifying clinically meaningful fatigue with the Fatigue Symptom Inventory.

Authors:  Kristine A Donovan; Paul B Jacobsen; Brent J Small; Pamela N Munster; Michael A Andrykowski
Journal:  J Pain Symptom Manage       Date:  2008-05-20       Impact factor: 3.612

4.  Docetaxel-related fatigue in men with metastatic prostate cancer: a descriptive analysis.

Authors:  A R T Bergin; E Hovey; A Lloyd; G Marx; P Parente; T Rapke; P de Souza
Journal:  Support Care Cancer       Date:  2017-04-20       Impact factor: 3.603

5.  Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy.

Authors:  Elizabeth Hovey; Paul de Souza; Gavin Marx; Phillip Parente; Tal Rapke; Andrew Hill; Antonino Bonaventura; Antony Michele; Paul Craft; Ehtesham Abdi; Andrew Lloyd
Journal:  Support Care Cancer       Date:  2013-12-17       Impact factor: 3.603

6.  Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study.

Authors:  Ian Hickie; Tracey Davenport; Denis Wakefield; Ute Vollmer-Conna; Barbara Cameron; Suzanne D Vernon; William C Reeves; Andrew Lloyd
Journal:  BMJ       Date:  2006-09-01

7.  Development and validation of a 6-day standard for the identification of frequent mental distress.

Authors:  Robert M Bossarte; Hua He; Cynthia A Claassen; Kerry Knox; Xin Tu
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2010-04-17       Impact factor: 4.328

Review 8.  Aiming for a better understanding and management of cancer-related fatigue.

Authors:  Elisabeth C W Neefjes; Maurice J D L van der Vorst; Susanne Blauwhoff-Buskermolen; Henk M W Verheul
Journal:  Oncologist       Date:  2013-09-13

9.  Cross-cultural development of an item list for computer-adaptive testing of fatigue in oncological patients.

Authors:  Johannes M Giesinger; Morten Aa Petersen; Mogens Groenvold; Neil K Aaronson; Juan I Arraras; Thierry Conroy; Eva M Gamper; Georg Kemmler; Madeleine T King; Anne S Oberguggenberger; Galina Velikova; Teresa Young; Bernhard Holzner
Journal:  Health Qual Life Outcomes       Date:  2011-03-29       Impact factor: 3.186

10.  Specific and number of comorbidities are associated with increased levels of temporomandibular pain intensity and duration.

Authors:  Haissam Dahan; Yoram Shir; Ana Velly; Paul Allison
Journal:  J Headache Pain       Date:  2015-05-20       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.